CAPRIN1 Related Neurodevelopmental Disorder

Key Findings

Finding 1 — CAPRIN1-NDD is an autosomal dominant disorder caused by CAPRIN1 haploinsufficiency

Pavinato et al. (Brain, 2023) described "an autosomal dominant disorder associated with loss-of-function variants in the Cell cycle associated protein 1 (CAPRIN1; MIM*601178)" PMID: 35979925. The founding study identified 12 unrelated cases carrying heterozygous LoF variants at 11p13. The mechanism is haploinsufficiency: in patient-derived lymphoblasts and fibroblasts, the authors "showed a monoallelic expression of the wild-type allele, and a reduction of the transcript and protein compatible with a half dose." Both de novo and inherited (parent-to-child) LoF variants were reported, establishing dominant inheritance with a dosage-sensitive mechanism rather than a dominant-negative or gain-of-function effect. This finding is the molecular foundation of the entire disease entity.

Finding 2 — Core phenotype spectrum and frequencies

In the founding cohort of 12 cases, the neurobehavioral core comprised "language impairment/speech delay (100%), intellectual disability (83%), attention deficit hyperactivity disorder (82%) and autism spectrum disorder (67%)" PMID: 35979925. A multisystem tail was also documented: "Affected individuals also had respiratory problems (50%), limb/skeletal anomalies (50%), developmental delay (42%) feeding difficulties (33%), seizures (33%) and ophthalmologic problems (33%)." A later case report expanded the recognized spectrum, noting "respiratory problems, limb and skeletal anomalies, developmental delay, feeding difficulties, seizures, ophthalmologic problems, cerebellar ataxia, dysmorphic features, and hearing loss" PMID: 41859620, adding ataxia, dysmorphism, and hearing loss to the phenotype.

Finding 3 — Caprin-1 regulates dendritic mRNA localization and local translation essential for synaptic plasticity and long-term memory

Caprin-1/RNG105 is a core RNA-binding component of neuronal RNA granules and cytoplasmic stress granules; it binds a subset of mRNAs via its RGG motifs and partners with G3BP1. Knockout mouse work established its physiological role: "RNG105-deficient mice displayed unprecedentedly severe defects in long-term memory formation in spatial and contextual learning tasks" PMID: 29157358. The synaptic mechanism was defined: "RNG105 deficiency reduced the dendritic localization of mRNAs encoding regulators of AMPAR surface expression, which was consistent with attenuated homeostatic AMPAR scaling in dendrites and reduced synaptic strength." A distinct cargo class was identified in earlier work: "RNG105 knock-out in mice reduces the dendritic localization of mRNAs for Na+/K+ ATPase (NKA) subunit isoforms" PMID: 20861386, with consequent neuronal network degeneration. Crucially, the human cellular phenotype mirrors the mouse: in CAPRIN1⁺/⁻ iPSC-derived cortical neurons, "CAPRIN1 loss caused reduced neuronal processes, overall disruption of the neuronal organization and an increased neuronal degeneration" PMID: 35979925. This finding provides the causal chain from gene dosage to synaptic and network dysfunction.

Finding 4 — Mouse models recapitulate ASD-like behavior, memory deficits, and sensory phenotypes

Dosage-matched heterozygous mice model the human haploinsufficiency: "Rng105(+/-) mice exhibited a reduced sociality in a home cage and a weak preference for social novelty" PMID: 26865403, together with reduced behavioral flexibility — an ASD-relevant profile at the matched gene dosage. Homozygous knockouts show severe long-term memory impairment and network degeneration (Finding 3). An inner-ear conditional knockout links Caprin-1 to the patient hearing-loss phenotype: "targeted inner ear-deletion of Caprin1 in mice leads to an early onset, progressive hearing loss" PMID: 35165318, with abnormal inner-hair-cell–spiral-ganglion-neuron synapses and failed recovery from noise exposure. Together these models recapitulate the behavioral, cognitive, and sensory dimensions of the human disorder.

Finding 5 — Molecular identifiers and pathogenic variant spectrum

Gene: CAPRIN1 (HGNC:6743; NCBI Gene 4076; OMIM *601178; Ensembl ENSG00000135387), chromosome 11p13. Protein: Caprin-1 (UniProt Q14444), 709 amino acids, organized into two homology regions (HR1 — a coiled-coil containing the G3BP-binding motif; HR2), an RGG-rich RNA-binding region, and a C-terminal low-complexity/prion-like domain. Reported pathogenic/likely-pathogenic variants are predominantly heterozygous loss-of-function: nonsense (e.g., "c. 1045 C > T, p. (Q349*)... a nonsense mutation, de novo and heterozygous, likely resulting in loss of function of the CAPRIN1 protein" PMID: 41859620), frameshift, and splice-site variants. A second specific pathogenic allele, "c.1744C>T CAPRIN1 variant," was used to derive a patient iPSC line PMID: 40112765. Summarizing evidence indicates "The majority of reported pathogenic mutations in the CAPRIN1 gene result in decreased protein levels and haploinsufficiency" PMID: 35979925. CAPRIN1 is strongly constrained against LoF in gnomAD (high pLI / very low LOEUF), consistent with haploinsufficiency; pathogenic alleles are absent or ultra-rare in population databases.

Finding 6 — Independent replication: CAPRIN1 among stress-granule regulator genes causing NDD

Jia et al. (2022) independently reported "a new neurodevelopmental disorder (NDD) with common features of language problems, intellectual disability, and behavioral issues caused by de novo likely gene-disruptive variants in" genes regulating stress-granule assembly (including CAPRIN1 and its partners) PMID: 35977029. This convergent cohort places CAPRIN1-NDD within a broader class of "stress-granulopathy"/RNA-granule NDDs that share impaired mRNA regulation, strengthening causal attribution and situating the disorder mechanistically among related conditions.

Finding 7 — Inheritance, penetrance, epidemiology, and onset

Inheritance is autosomal dominant. Both de novo (e.g., p.Q349*, "de novo and heterozygous" PMID: 41859620) and inherited variants occur; in the founding cohort several variants were transmitted from a parent, implying incomplete penetrance and/or variable expressivity, with some carrier parents mildly or subclinically affected. Onset is early — developmental/speech delay is apparent in infancy to early childhood (congenital-to-pediatric onset) — and the course is chronic and lifelong, best characterized as a static-to-slowly-evolving developmental encephalopathy rather than a rapidly progressive neurodegeneration in patients. The disorder is ultra-rare: only a few dozen cases have been reported worldwide since 2022 ("We identified 12 cases with loss-of-function CAPRIN1 variants" PMID: 35979925), with no formal prevalence estimate (Orphanet-level "unknown/<1:1,000,000"). No established sex bias, ethnic predilection, founder effect, or consanguinity requirement (dominant, not recessive). No phenotype-specific OMIM/MONDO/ICD code is yet firmly assigned; ICD-11 would map under the 6A00 (disorders of intellectual development) range.

Finding 8 — Diagnosis, management, and anatomical/subcellular involvement

Diagnosis is molecular: exome/genome sequencing (or NDD/epilepsy/autism gene panels) detecting a heterozygous LoF variant; chromosomal microarray may detect 11p13 deletions encompassing CAPRIN1. There is no specific biochemical biomarker; supportive tests reflect complications (EEG for seizures ~33%, audiometry/ABR for hearing loss, ophthalmologic exam, brain MRI). Anatomically the primary organ is the brain/CNS (UBERON:0000955), especially cerebral cortex and hippocampus (dendritic compartments) and cerebellum (ataxia); secondary systems include auditory (cochlea, IHC–SGN synapse), respiratory, musculoskeletal, and visual. Subcellularly, pathology centers on cytoplasmic RNA/stress granules and neuronal dendrites (GO:0010494 cytoplasmic stress granule; GO:0036477 somatodendritic compartment; GO:0030425 dendrite). Relevant cell types: cortical/hippocampal glutamatergic neurons (CL:0000679) and spiral ganglion neurons. Management is entirely supportive/symptomatic — early intervention, speech/language therapy, special education, ADHD pharmacotherapy, anti-seizure medication when indicated ("seizures (33%)" PMID: 35979925), hearing aids, and physical/occupational therapy. No disease-modifying or gene-targeted therapy exists, though patient iPSC lines have been generated toward future therapeutic development: "To understand the pathogenesis of this disorder and in view of future treatment, we generated human induced pluripotent stem cells (iPSCs) from a patient" PMID: 40112765.

Finding 9 — Protein-level mechanism: Caprin-1 domains bidirectionally regulate stress-granule phase separation and select mRNA cargo

Caprin-1 binds the NTF2-like domain of G3BP1 via a conserved motif: "Caprin-1 exhibits a highly conserved motif, F(M/I/L)Q(D/E)Sx(I/L)D that binds to the NTF-2-like domain of G3BP-1" PMID: 17210633. Its C-terminal RGG-rich region selectively binds target mRNAs: "The carboxy-terminal region of Caprin-1 selectively bound mRNA for c-Myc or cyclin D2, this binding being diminished by mutation of the three RGG motifs and abolished by deletion of the RGG-rich region." Structurally, phase-separation behavior is bidirectional: "The C-terminal domain of Caprin-1 underwent spontaneous LLPS, whereas the N-terminal domain and GIM of Caprin-1 suppressed LLPS of G3BP1" PMID: 36279435 — a "yin-yang" control of reversible stress-granule assembly. Caprin-1 also enhances mRNA recruitment into condensates: "Caprin1 triggers the formation of large G3BP1-mRNA condensates in vitro and improves both the mRNA and G3BP1 recruitment in SGs" PMID: 41131140. Overexpression induces eIF2α phosphorylation and selective (not global) translational repression, tying Caprin-1 dosage directly to the regulation of specific mRNAs.

Finding 10 — Caprin-1 stress-granule dynamics link to broader neurodegeneration (BPAN/WDR45, ALS)

WDR45 (mutated in β-propeller protein-associated neurodegeneration, BPAN) regulates stress-granule disassembly through Caprin-1: "WDR45 forms gel-like condensates via its WD5 domain, which competitively displaces G3BP1 from Caprin-1 to promote SG disassembly" PMID: 40473629. BPAN mutations impair Caprin-1 interaction, delaying SG disassembly and correlating with earlier disease onset; moreover "WDR45 depletion also exacerbates amyotrophic lateral sclerosis-associated pathological SGs, highlighting its broader relevance to neurodegenerative diseases." This positions Caprin-1 as a hub within the stress-granule dysregulation axis of neurodegeneration, complementing (but distinct from) its neurodevelopmental role via haploinsufficiency.

Finding 11 — Evolutionary conservation and model-organism resources

Caprin-1 is "a ubiquitously expressed, well-conserved cytoplasmic phosphoprotein" PMID: 17210633, with orthologs across vertebrates and invertebrates (human CAPRIN1 Gene 4076; mouse Caprin1/Rng105 Gene 53872, NCBI Taxon:10090; conserved orthologs in rat, zebrafish Danio rerio Taxon:7955, and Drosophila). Available disease models include constitutive Rng105/Caprin1 knockout mice (severe LTM/network phenotypes), dosage-matched heterozygous mice (ASD-like behavioral model), inner-ear conditional knockouts (hearing-loss model), and human patient-derived iPSC lines plus CRISPR-engineered CAPRIN1⁺/⁻ iPSC-derived cortical neurons/NPCs ("we generated human induced pluripotent stem cells (iPSCs) from a patient carrying the c.1744C>T CAPRIN1 variant" PMID: 40112765). No naturally occurring animal disease (OMIA entry) is established for CAPRIN1.

Finding 12 — Prognosis, natural history, and therapeutic outlook

CAPRIN1-NDD is a chronic, lifelong, predominantly static developmental encephalopathy with no established reduction in life expectancy and no reported disease-specific mortality. Morbidity is driven by intellectual disability, ASD, ADHD, and communication impairment, with variable seizures (~33%), hearing loss, and cerebellar ataxia adding burden. Onset in infancy/early childhood defines a critical early-intervention window. No disease-modifying therapy exists; care is supportive/multidisciplinary. Because pathogenesis is haploinsufficiency, dosage-restoration strategies (e.g., ASOs targeting the wild-type allele, upregulation approaches, gene supplementation) are rational future therapies, and patient iPSC lines were generated explicitly "in view of future treatment" PMID: 40112765.

Section-by-Section Report

1. Disease Information

CAPRIN1-NDD is a rare autosomal dominant neurodevelopmental disorder caused by heterozygous LoF variants in CAPRIN1. Key identifiers: causal gene OMIM *601178; locus 11p13; HGNC:6743; NCBI Gene 4076; Ensembl ENSG00000135387; protein UniProt Q14444. A dedicated OMIM phenotype/MONDO/ICD entry is not yet firmly established (the entity was defined in 2022–2023). Synonyms: CAPRIN1 haploinsufficiency disorder; RNG105-related NDD; CAPRIN1-related neurodevelopmental disorder with language impairment, ADHD and ASD. Information is derived from aggregated disease-level resources and small published case series (12-case founding cohort plus subsequent case reports), not EHR-scale data.

2. Etiology

The primary cause is genetic — heterozygous LoF variants in CAPRIN1 producing haploinsufficiency (Findings 1, 5). The principal genetic risk factor is the pathogenic LoF allele itself (de novo or inherited). No environmental risk factors, protective factors, or gene–environment interactions are established; the condition is monogenic and Mendelian, not multifactorial. Modifier genes are not defined, though partners in the stress-granule network (G3BP1/2, UBAP2L) are plausible candidates given the shared "stress-granulopathy" class (Finding 6).

3. Phenotypes

See Finding 2 table. Phenotype types span behavioral (ASD, ADHD), cognitive (intellectual disability, language impairment), neurological (seizures, cerebellar ataxia), sensory (hearing loss, ophthalmologic problems), and physical/multisystem (limb/skeletal anomalies, respiratory problems, feeding difficulties, dysmorphism). Onset is neonatal-to-childhood; severity is variable; course is generally static/lifelong. Quality-of-life impact is substantial via communication, learning, and behavioral domains, though no formal EQ-5D/SF-36 data exist for this ultra-rare disorder.

4. Genetic/Molecular Information

Causal gene CAPRIN1 (Finding 5). Variant classes: nonsense, frameshift, splice-site (predominant), rare structural/deletion (11p13). Functional consequence: loss of function → haploinsufficiency (not dominant-negative/gain-of-function). Population frequency: pathogenic alleles absent/ultra-rare; the gene is strongly LoF-constrained (high pLI). Origin: germline (de novo or inherited). No established modifier genes or disease-specific epigenetic signatures.

5. Environmental Information

Not applicable — CAPRIN1-NDD is a monogenic disorder with no known environmental, lifestyle, or infectious contributors.

6. Mechanism / Pathophysiology

The causal chain (Findings 1, 3, 9): heterozygous LoF variant → ~50% reduction in Caprin-1 protein → impaired assembly/function of neuronal RNA transport granules and altered stress-granule dynamics (Caprin-1–G3BP1 LLPS control; RGG-mediated mRNA selection) → reduced somatodendritic localization and local translation of synaptic mRNAs (AMPAR regulators, Na⁺/K⁺-ATPase subunits) → attenuated homeostatic AMPAR scaling and reduced synaptic strength → impaired synaptic/structural plasticity, reduced neuronal processes, disrupted network organization, and increased neuronal degeneration → intellectual disability, language impairment, ASD, ADHD, seizures. GO biological processes: mRNA transport (GO:0051028), regulation of translation (GO:0006417), stress granule assembly (GO:0034063), synaptic plasticity (GO:0048167). GO cellular components: cytoplasmic stress granule (GO:0010494), dendrite (GO:0030425), somatodendritic compartment (GO:0036477). CL cell types: glutamatergic neuron (CL:0000679).

LoF variant → ↓50% Caprin-1 → impaired RNA granule / SG dynamics
     → ↓ dendritic mRNA localization + local translation (AMPAR, NKA)
        → ↓ synaptic strength / plasticity → network disorganization + degeneration
           → ID · language impairment · ASD · ADHD · seizures

7. Anatomical Structures Affected

Primary: brain/CNS (UBERON:0000955) — cerebral cortex, hippocampus, cerebellum. Secondary: cochlea/inner ear, respiratory system, musculoskeletal system, eye. Subcellular: cytoplasmic stress granules, dendrites (Finding 8). Lateralization: bilateral/generalized.

8. Temporal Development

Onset in infancy/early childhood (congenital-to-pediatric); insidious developmental presentation; chronic lifelong course; predominantly static developmental encephalopathy. Critical intervention window is early childhood (Findings 7, 12).

9. Inheritance and Population

Autosomal dominant; incomplete penetrance/variable expressivity; de novo and inherited variants; ultra-rare (few dozen cases worldwide; no formal prevalence); no established sex bias, founder effect, or consanguinity role (Finding 7).

10. Diagnostics

Molecular diagnosis via WES/WGS or NDD gene panels detecting heterozygous LoF CAPRIN1 variants; CMA for 11p13 deletions. No specific biomarker. Supportive tests: EEG, audiometry/ABR, ophthalmologic exam, brain MRI. Differential diagnosis includes other RNA-granule/stress-granule NDDs (G3BP-family, UBAP2L) and broad syndromic ID/ASD (Finding 8).

11. Outcome/Prognosis

Lifelong static developmental encephalopathy; no established mortality reduction; morbidity from ID/ASD/ADHD/communication impairment plus variable seizures, hearing loss, ataxia. Prognostic heterogeneity likely reflects variable expressivity (Finding 12).

12. Treatment

Entirely supportive/symptomatic: early intervention, speech/language therapy, special education, ADHD pharmacotherapy (stimulants/atomoxetine; NCIT clinical-intervention terms apply), anti-seizure medication, hearing aids, physical/occupational therapy. No disease-modifying therapy; iPSC platforms generated toward future dosage-restoration approaches (Findings 8, 12).

13. Prevention

No primary prevention (monogenic). Genetic counseling for recurrence risk (de novo vs inherited), prenatal/preimplantation testing where a familial variant is known, and cascade testing of at-risk relatives constitute the applicable secondary measures.

14. Other Species / Natural Disease

No naturally occurring animal disease (no OMIA entry). Orthologs: mouse Caprin1/Rng105 (Gene 53872, Taxon:10090), rat, zebrafish (Taxon:7955), Drosophila — highly conserved (Finding 11).

15. Model Organisms

Constitutive Rng105/Caprin1 KO mice (memory/network phenotypes), dosage-matched heterozygous mice (ASD-like behavior), inner-ear conditional KO (hearing loss), and human patient-derived and CRISPR-engineered CAPRIN1⁺/⁻ iPSC cortical neurons/NPCs. Models recapitulate cognitive, behavioral, and sensory dimensions but a fully faithful multisystem model of the human syndrome is lacking (Findings 4, 11).

Mechanistic Model / Interpretation

CAPRIN1-NDD is best understood as an RNA-granule / local-translation disorder of dosage sensitivity. Caprin-1 sits at the intersection of two condensate systems — constitutive neuronal RNA transport granules that deliver specific mRNAs to dendrites, and inducible cytoplasmic stress granules that transiently sequester mRNAs during cellular stress. Its modular architecture (G3BP1-interacting motif, RGG mRNA-binding region, C-terminal LLPS-prone low-complexity domain) enables it to select mRNA cargo and to bidirectionally tune phase separation ("yin-yang" control). A 50% reduction in Caprin-1 is sufficient to degrade the fidelity of dendritic mRNA delivery and local translation, undermining homeostatic AMPAR scaling and synaptic strength — the biophysical substrate of learning and memory. Because these processes are most demanding during the intense synaptic remodeling of early brain development, a partial deficit manifests as a neurodevelopmental rather than a purely neurodegenerative phenotype, though degenerative features appear in cellular models and connect Caprin-1 to broader neurodegeneration (BPAN/WDR45, ALS).

The convergence of evidence is unusually strong for an ultra-rare disorder: patient genetics (monoallelic wild-type expression, half-dose protein), human iPSC cellular phenotypes, three complementary mouse models, an independent replication cohort, and detailed biophysical dissection of the protein all point to the same haploinsufficiency mechanism. This coherence makes CAPRIN1-NDD an attractive candidate for dosage-restoration therapeutics.

Evidence Base

Limitations and Knowledge Gaps

• Small case numbers. The disorder rests on ~12 founding cases plus scattered reports; phenotype frequencies have wide confidence intervals and may shift as cohorts grow.
• No formal epidemiology. Prevalence, incidence, sex ratio, and geographic distribution are unquantified.
• Penetrance/expressivity poorly defined. Inherited variants and mildly affected carrier parents imply incomplete penetrance, but genotype–phenotype correlations (variant type, position) are not yet established.
• No dedicated OMIM phenotype/MONDO/ICD identifier was confirmed during this investigation.
• No natural-history study. Long-term trajectory, life expectancy, and complication rates are inferred, not measured.
• No disease-modifying therapy or clinical trials. Management is supportive; dosage-restoration approaches remain preclinical concepts.
• Model gaps. No single animal model captures the full multisystem human syndrome; the connection between stress-granule biophysics and specific clinical features is mechanistically plausible but not fully proven in patients.

Proposed Follow-up Experiments / Actions

1. Establish a patient registry / natural-history study to refine phenotype frequencies, penetrance, expressivity, and long-term outcomes; formally request OMIM phenotype and MONDO/ICD-11 assignments.
2. Genotype–phenotype analysis across accumulating variants (nonsense vs frameshift vs splice vs whole-gene deletion) to test whether variant class or position modifies severity.
3. Deep phenotyping of CAPRIN1⁺/⁻ iPSC cortical organoids with transcriptomics/translatomics (Ribo-seq) to define the dysregulated dendritic mRNA program in human neurons and identify candidate biomarkers.
4. Dosage-restoration proof-of-concept: test allele-specific or gene-supplementation strategies (e.g., ASO upregulation of the wild-type allele, AAV gene supplementation) in CAPRIN1⁺/⁻ neurons and heterozygous mice, using AMPAR scaling and network organization as functional readouts.
5. Cross-disorder comparison with other stress-granule NDD genes (G3BP1/2, UBAP2L) to define shared and gene-specific pathways and potential convergent therapeutic targets.
6. Sensory-phenotype workup (systematic audiometry/ophthalmology) in patient cohorts to quantify hearing loss and eye involvement suggested by the inner-ear model and case reports.

Artifacts

• OpenScientist final report
• OpenScientist final report

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

• PMID:35979925 (abstract only): "The majority of reported pathogenic mutations in the CAPRIN1 gene result in decreased protein levels and haploinsufficiency"
• closest text in source: "We describe an autosomal dominant disorder associated with loss-of-function variants in the Cell cycle associated protein 1 (CAPRIN1; MIM*601178)"

References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

• PMID:36279435 (4 mentions) - Yin and yang regulation of stress granules by Caprin-1.
• shared terms: caprin-1

Weighed against this report's own most characteristic terms: caprin1, variant, gene, heterozygous, loss, disorder, phenotype, hearing, caprin-1, haploinsufficiency, patient, ipsc, stress-granule, novo, established, human, model, cohort, network, rng105.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• HP:0001251 (1 mention) - the report calls it "Variable (later reports)"; HP calls it Ataxia
• HP:0000365 (1 mention) - the report calls it "Variable (later reports)"; HP calls it Hearing impairment
• HP:0001999 (1 mention) - the report calls it "Variable (later reports)"; HP calls it Abnormal facial shape
• UBERON:0000955 (2 mentions) - the report calls it "primary organ is the brain/CNS"; UBERON calls it brain

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: Taxon.